We have successfully developed several SMA micelles of anticancer agents including doxorubicin, pirarubicin, and ZnPP, all of which showed stable micelle structures in physiological aqueous solutions and in circulation, and the albumin-binding property of SMA further renders prolonged circulation time and improved stability of SMA micelles, consequently achieving tumor-targeted therapeutic effects [22,34,35]. This evidence concerns the gene ALB and neoplasm.